Harvey Schwartz
Neurology · Hollywood, FLNPI 1396796066
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,091 of the $7,608 with a category attached, or 80.1%. It is spread thinly across 37 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,849 and has fallen 53.9% since, to $852 in 2025.
Across 331 payments — averaging $22.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sage Therapeutics, LLC$2K
- AbbVie$2K
- Amgen$614
- Lilly USA, LLC$423
- Sanofi$287
- Biogen$283
- plus $3K from 31 others
Across 203 payments — averaging $29,060 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.2M
- Biogen$1.7M
- Modernatx, Inc.$1.5M
- Eisai Inc.$239K
- Sage Therapeutics, LLC$122K
- Novartis$89K
- plus $87K from 5 others
What the payments were for
- Speaking & faculty fees$350%
- Travel & lodging$1,33518%
- Food & beverage$6,09180%
- Education$1472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sage Therapeutics, LLC | 10 | $1,660 |
| AbbVie(2 entities) | 115 | $1,610 |
| Amgen | 22 | $614 |
| Lilly USA, LLC | 31 | $423 |
| Sanofi | 2 | $287 |
| Biogen | 14 | $283 |
| Adamas Pharmaceuticals, Inc. | 15 | $232 |
| Biohaven Pharmaceuticals, Inc. | 16 | $228 |
| Impel Pharmaceuticals Inc. | 12 | $225 |
| Teva Pharmaceuticals USA, Inc. | 11 | $210 |
| AstraZeneca | 4 | $207 |
| Novartis | 14 | $195 |
| Sunovion Pharmaceuticals Inc. | 10 | $183 |
| Johnson & Johnson(2 entities) | 5 | $177 |
| GSK | 1 | $120 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $108 |
| Amneal Pharmaceuticals LLC | 6 | $90 |
| Supernus Pharmaceuticals, Inc. | 6 | $82 |
| Neurocrine Biosciences, Inc. | 4 | $72 |
| UCB, Inc. | 2 | $68 |
| Upsher-smith Laboratories LLC | 3 | $60 |
| Eisai Inc. | 3 | $49 |
| Lundbeck LLC | 2 | $49 |
| Tanabe Pharma America, Inc. | 2 | $47 |
| Avanir Pharmaceuticals, Inc. | 2 | $36 |
| Sanofi-aventis U.S. LLC | 1 | $35 |
| Acorda Therapeutics, Inc | 2 | $35 |
| Abbott | 1 | $29 |
| Argenx US, Inc. | 2 | $28 |
| EMD Serono, Inc. | 1 | $28 |
| Corium, LLC | 1 | $25 |
| Zyla Life Sciences, Inc. | 1 | $23 |
| Bausch Health US, LLC | 1 | $23 |
| Harmony Biosciences LLC | 1 | $23 |
| Livanova USA, Inc. | 1 | $21 |
| GE HealthCare | 1 | $13 |
| Kyowa Kirin, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,608 in reported general payments places this provider in the 70th percentile of 1,434 neurology providers in Florida.
Other neurology in Hollywood
- Buse SengulHollywood$189K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.